Literature DB >> 28361526

Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.

F Álvarez Lerma1, R Muñoz Bermudez, S Grau, M P Gracia Arnillas, L Sorli, L Recasens, M Mico García.   

Abstract

The use of colistin for the treatment of multiresistant bacteria has led to the emergence of colistin-resistant strains of Gram-negative bacilli. Treatment of infections caused by these pan-drug-resistant bacteria is difficult owing to the paucity of effective antibiotics. We report two cases of ventilator-associated respiratory infection caused by pan-drug-resistant, colistin-resistant Pseudomonas aeruginosa that were successfully treated with ceftolozane-tazobactam.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28361526

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  4 in total

1.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

Review 2.  Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.

Authors:  Luca Gregorio Giaccari; Maria Caterina Pace; Maria Beatrice Passavanti; Francesca Gargano; Caterina Aurilio; Pasquale Sansone
Journal:  Life (Basel)       Date:  2021-05-24

3.  Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.

Authors:  J Monterrubio-Villar; S Rodríguez-Garrido; J D Jiménez-Delgado
Journal:  Rev Esp Quimioter       Date:  2018-07-09       Impact factor: 1.553

Review 4.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.